Scribe Therapeutics, Inc.

SCTX Nasdaq SEC CIK 1853921
Follow Scribe Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.6M −91.9% vs same quarter last year
Net income −$9.9M −770% vs same quarter last year
EPS, diluted −$0.68
Operating cash flow −$11.3M +0.4% vs same quarter last year
Revenue by quarter
$4.9M
$20.1M
$1.9M
$1.6M
Q2 25 Q3 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing